We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
BMC Positions:
Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)

Input to PMPRB Regarding Proposed Guideline Revisions Related to Gap Medicines, Comparator Countries and International Price Tests (August 31, 2021)

Input Regarding PMPRB Proposed Guideline Monitoring and Evaluation Plan (June 21, 2021)

Letter Responding to PMPRB Board Chair (June 8, 2021) (français)

Letter to the Prime Minister Regarding PMPRB (May 28, 2021) (français)

Submission to Finance Canada: Priorities for the Federal Budget (February 18, 2021)

Submission to the Standing Committee on Health: PMPRB Guidelines (November 6, 2020) (français)

Letter to the Minister of Health (August 10, 2020) (français)

Submission to the House of Commons Standing Committee on Finance (August 2020)

Submission Regarding PMPRB Revised Draft Guidelines (August 2020) (français)

Letter to the Minister of Health (June 19, 2020) (français)

Submission to the House of Commons Standing Committee on Health (May 2020)

Submission Regarding Draft Guidelines to Implement the Patented Medicines Regulations, as amended (February 2020)

Letter to Health Canada Regarding Proposed Patented Medicines Regulations (February 2018)

Submission Regarding PMPRB Modernization (October 2016)